Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00171223

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial

Official title:
An Extension to a Phase II Study to Determine the Efficacy and Safety of STI571 in Patients With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

Clinical Trial Summary

During the Core Phase of the study, participants received STI571 at a dose of 400 milligrams (mg) daily for up to 12 months. Participants completing 12 months of therapy were eligible to continue treatment in the Extension Phase of the study provided that, in the opinion of the investigator, they had benefited from treatment with STI571 and there were no safety concerns.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00171223
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date December 6, 1999
Completion date November 29, 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT01437202 - Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia N/A
Completed NCT02896842 - A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML Phase 2
Withdrawn NCT02421926 - Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
Completed NCT01768689 - Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia N/A
Not yet recruiting NCT02903277 - National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent N/A
Completed NCT03090477 - Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients N/A
Active, not recruiting NCT02885766 - Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene Phase 1/Phase 2
Recruiting NCT01464411 - Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan N/A
Completed NCT01602952 - Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Phase 1/Phase 2
Not yet recruiting NCT02687425 - Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia Phase 2
Recruiting NCT04877522 - Asciminib Roll-over Study Phase 4
Completed NCT01511289 - Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients Phase 3
Completed NCT02480608 - Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) Phase 1/Phase 2
Completed NCT02389972 - Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study N/A
Completed NCT01774630 - Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) Phase 2